The Indian government has decided to cap trade margins at 30% of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs. This new regulation covers 110 medicines, including 35 patented drugs, and is expected to be implemented later this month. The decision aims to make cancer treatment more affordable for patients across the country.
- The cap applies to trade margins on 110 non-scheduled anti-cancer drugs.
- It includes 35 patented medicines.
- Pharma and hospital stocks rose up to 6% after the announcement.
- The measure is expected to reduce medicine prices by up to 70%.
- Cancer patients could save approximately ₹2,500 crore annually.
What is the trade margin cap on anti-cancer drugs?
Trade margin is the difference between the price at which a drug is supplied to distributors or retailers and the price at which it is sold to patients. The government has capped this margin at 30% of the MRP for all non-scheduled anti-cancer drugs. This means that the profit margin for distributors and retailers on these medicines cannot exceed 30% of the final retail price.
Which medicines are affected by this new rule?
The cap covers 110 non-scheduled anti-cancer medicines, including 35 patented drugs. Non-scheduled drugs are those that are not part of the essential medicines list with existing government price controls. An expert committee under the Directorate General of Health Services (DGHS) will finalize the exact list of medicines covered by this cap.
How did the stock market react to the announcement?
Shares of pharmaceutical companies such as Sun Pharmaceutical and Dr Reddy’s Laboratories, along with hospital operators like Max Healthcare, Fortis Healthcare, Apollo Hospitals, and Medanta, surged by up to 6% on October 9, 2026. The Nifty Healthcare index rose 1.3% to an intraday high of 15,902.45 points, reflecting investor optimism as uncertainty eased after the announcement.
What is the expected impact on pharmaceutical companies and hospitals?
While the margin cap may reduce profits for pharmaceutical companies selling high-priced anti-cancer drugs, analysts expect this impact to be temporary and manageable. The effect on individual companies depends on their exposure to the affected medicines and their current trade margins.
Hospitals may offset some losses by adjusting prices for related services such as drug administration charges. According to Goldman Sachs analysts, hospitals typically earn margins of 30-50% on oncology drugs, allowing some flexibility to recoup revenue.
How will this benefit cancer patients?
The Department of Pharmaceuticals estimates that the 30% margin cap could reduce medicine prices by up to 70%. This significant price reduction is expected to save cancer patients around ₹2,500 crore annually, lowering their out-of-pocket expenses for treatment.
Previously, only essential medicines under the scheduled list were subject to strict government price ceilings. This new measure extends price protection to non-scheduled anti-cancer drugs, broadening access to affordable cancer care.
Frequently Asked Questions
Q: What is the difference between scheduled and non-scheduled drugs?
A: Scheduled drugs are those listed under the essential medicines list with government-set price ceilings. Non-scheduled drugs do not have such price controls, but the new margin cap now applies to certain non-scheduled anti-cancer medicines.
Q: When will the margin cap be implemented?
A: The cap is expected to be implemented later in October 2026, after the expert committee finalizes the list of medicines covered.
Q: Will this affect the availability of anti-cancer drugs?
A: The government aims to make cancer drugs more affordable without disrupting supply. The impact on availability will depend on how companies adjust to the new pricing rules.
